Defence Therapeutics (TSE:DTC) has released an update.
Defence Therapeutics Inc., a Canadian biopharmaceutical company, has announced its upcoming participation in the Society of Nuclear Medicine and Molecular Imaging Annual Meeting in Toronto on June 11, 2024. The company is developing a promising new Radio-Immuno-Conjugate called AccuTRIC, aimed at effectively treating difficult cancers by utilizing advanced radiotherapeutics with their proprietary ACCUM technology. This participation underscores Defence’s role in advancing cancer therapy innovations within the global medical community.
For further insights into TSE:DTC stock, check out TipRanks’ Stock Analysis page.
